Neuberger Berman Group LLC Has $14.97 Million Holdings in STERIS plc $STE

Neuberger Berman Group LLC boosted its position in STERIS plc (NYSE:STE) by 211.5% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 60,490 shares of the medical equipment provider’s stock after purchasing an additional 41,074 shares during the period. Neuberger Berman Group LLC’s holdings in STERIS were worth $14,968,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of STE. Steigerwald Gordon & Koch Inc. acquired a new position in shares of STERIS in the 3rd quarter valued at about $25,000. Geneos Wealth Management Inc. grew its stake in STERIS by 416.0% during the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 104 shares during the period. Cloud Capital Management LLC bought a new stake in STERIS in the third quarter worth approximately $29,000. TruNorth Capital Management LLC bought a new stake in STERIS in the third quarter worth approximately $37,000. Finally, Root Financial Partners LLC acquired a new position in STERIS in the third quarter valued at approximately $39,000. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the transaction, the director directly owned 705 shares of the company’s stock, valued at approximately $167,233.05. This trade represents a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.07% of the company’s stock.

Analyst Ratings Changes

STE has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, STERIS presently has an average rating of “Moderate Buy” and a consensus price target of $275.20.

STERIS Stock Down 3.4%

STE stock opened at $230.49 on Friday. The stock’s 50 day simple moving average is $254.37 and its 200 day simple moving average is $251.54. The company has a market cap of $22.60 billion, a P/E ratio of 32.15 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. STERIS plc has a fifty-two week low of $204.90 and a fifty-two week high of $269.44.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting the consensus estimate of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.During the same quarter in the prior year, the business earned $2.32 earnings per share. The business’s quarterly revenue was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, research analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, February 17th. STERIS’s payout ratio is 35.15%.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.